TORONTO, Sept. 27 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today announced the co-sponsorship with Toray Medical Company (Tokyo, Japan) of a key scientific session at SEPSIS 2007, an International Symposium held at the Institut Pasteur in Paris, France from September 26-29th, 2007. "Endotoxemia - Detection, Consequence and Intervention" will feature a panel of four thought leaders in the field of sepsis discussing the value of Spectral's EAA(TM) Endotoxin Activity Assay. The EAA(TM) is the only FDA cleared, whole blood assay for the detection of endotoxemia.
"There is growing recognition of the role that exdotoxins play in the onset of Sepsis, as is reflected by the number of sessions at this symposium that will address this topic," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "We are pleased to participate in SEPSIS 2007 as it gives us the opportunity to further demonstrate the utility of our EAA(TM) Endotoxin Activity Assay to a large group of clinicians who are focused on treating patients with Sepsis."
The "Endotoxemia - Detection, Consequence and Intervention" scientific session will take place on Friday, September 28, 2007 at the Institut Pasteur Auditorium at 16:30CEST and the panel will include International Sepsis Forum Chair, Dr. John Marshall of St. Michael's Hospital in Toronto, Canada. For further information please visit: http://www.sepsisforum.org.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products include Spectral's FDA approved rapid diagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis (EAA(TM)), as well as a range of other biological reagents. Spectral is listed on TSX under the symbol SDI.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
%SEDAR: 00002006E